Fortress Biotech (FBIO) on Thursday said that it has commenced a phase 2 trial to evaluate the safety, efficacy, and immunogenicity of Triplex in eliciting...
...
Journey Medical Corp., a subsidiary of Fortress Biotech (FBIO), on Friday priced its initial public offering of about 3.52 million common shares at $10...
| Address | 2 Gansevoort Street New York, New York 10014 |
| Phone | +1.781.652.4500 |
| Number of Employees | 88 |
| Recent SEC Filing | 12/07/2021 8-K |
| Chairman, President & Chief Executive Officer | Lindsay Allan Rosenwald |
| Chief Financial Officer, Secretary & Treasurer | Robyn M. Hunter |
| Senior Vice President-Biologics Operations | George C. Avgerinos |
| Director & Vice Chairman-Strategic Development | Michael Sean Weiss |
| Price Open | $2.27 |
| Previous Close | $2.12 |
| 52 Week Range | $1.94 - 6.10 |
| Market Capitalization | $211.2 M |
| Shares Outstanding | 99.6 M |
| Sector | Health Technology |
| Industry | Biotechnology | Next Earnings Announcement | 03/30/2022 |
| Call Open Interest (1d)* |  |
| Put Open Interest (1d)* | |
| Call Volume (1d)* | |
| Put Volume (1d)* | |
| Put Call Open Interest Ratio (1d)* | |
| Put Call Volume Ratio (1d)* | |
| * Data delayed by up to 15 minutes |
| Price / Earnings | N/A |
| Earnings per Share | -$0.81 |
| Beta vs. S&P 500 | N/A |
| Revenue | $26.9 M |
| Net Profit Margin | -59.80% |
| Return on Equity | -37.76% |
| Buy | |
| Overweight | |
| Hold | |
| Underweight | |
| Sell | |
Consensus Recommendation | |
